B. 1. Dameshek and W. , Some speculations on the myeloproliferative syndromes, Blood, vol.6, pp.372-375, 1951.

S. H. Swerdlow, International Agency for Research on Cancer & World Health Organization. WHO classification of tumours of haematopoietic and lymphoid tissues, International Agency for Research on Cancer, 2008.

P. C. Nowell and D. A. Hungerford, Chromosome studies on normal and leukemic human leukocytes, J. Natl. Cancer Inst, vol.25, pp.85-109, 1960.

J. D. Rowley, A New Consistent Chromosomal Abnormality in Chronic Myelogenous Leukaemia identified by Quinacrine Fluorescence and Giemsa Staining, Nature, vol.71, issue.5405, pp.290-293, 1973.
DOI : 10.1038/243290a0

P. J. Campbell and A. Green, The Myeloproliferative Disorders, New England Journal of Medicine, vol.355, issue.23, pp.2452-2466, 2006.
DOI : 10.1056/NEJMra063728

F. Delhommeau, Oncogenic mechanisms in myeloproliferative disorders, Cellular and Molecular Life Sciences, vol.63, issue.24
DOI : 10.1007/s00018-006-6272-7

A. Tefferi, R. Skoda, and J. W. Vardiman, Myeloproliferative neoplasms: contemporary diagnosis using histology and genetics, Nature Reviews Clinical Oncology, vol.133, issue.11, pp.627-637, 2009.
DOI : 10.1038/nrclinonc.2009.149

D. G. Savage, R. M. Szydlo, and J. M. Goldman, Clinical features at diagnosis in 430 patients with chronic myeloid leukaemia seen at a referral centre over a 16-year period, British Journal of Haematology, vol.96, issue.1
DOI : 10.1046/j.1365-2141.1997.d01-1982.x

J. J. Michiels, Philadelphia (Ph) chromosome-positive thrombocythemia without features of chronic myeloid leukemia in peripheral blood: natural history and diagnostic differentiation from Ph-negative essential thrombocythemia, Annals of Hematology, vol.83, issue.8, pp.504-512, 2004.
DOI : 10.1007/s00277-004-0877-4

D. Blickstein, BCR?ABL transcripts in bone marrow aspirates of Philadelphia?negative essential thrombocytopenia patients: clinical presentation, Blood, vol.90, pp.2768-2771, 1997.

D. P. Lebrun, Essential thrombocythemia with the Philadelphia chromosome and BCR-ABL gene rearrangement, Cancer Genetics and Cytogenetics, vol.54, issue.1, pp.21-25, 1991.
DOI : 10.1016/0165-4608(91)90025-P

F. Girodon, Philadelphia chromosome-positive thrombocythemia without features of chronic myeloid leukemia (CML) in peripheral blood, Annals of Hematology, vol.83, issue.6, pp.409-410, 2005.
DOI : 10.1007/s00277-004-0993-1

G. Emilia, Chronic myeloid leukemia with thrombocythemic onset may be associated with different BCR/ABL variant transcripts, Cancer Genetics and Cytogenetics, vol.101, issue.1, pp.75-77, 1998.
DOI : 10.1016/S0165-4608(97)00263-X

G. Damaj, Typical essential thrombocythaemia does not express bcr-abelson fusion transcript, British Journal of Haematology, vol.14, issue.4, pp.812-816, 2002.
DOI : 10.1093/jjco/hyd122

R. Marasca, Might essential thrombocythemia carry Ph anomaly? Blood 91, pp.3084-3085, 1998.

L. Rice and U. Popat, Every case of essential thrombocythemia should be tested for the Philadelphia chromosome, American Journal of Hematology, vol.98, issue.1, pp.71-73, 2005.
DOI : 10.1002/ajh.20257

J. Thiele, Philadelphia Chromosome???Negative Chronic Myeloproliferative Disease, American Journal of Clinical Pathology, vol.132, issue.2
DOI : 10.1309/AJCPR8GINMBDG9YG

J. Thiele and H. M. Kvasnicka, A critical reappraisal of the WHO classification of the chronic myeloproliferative disorders, Leukemia & Lymphoma, vol.63, issue.3, pp.381-396, 2006.
DOI : 10.1034/j.1600-0609.2002.02734.x

P. Mossuz, Diagnostic value of serum erythropoietin level in patients with absolute erythrocytosis, Haematologica, vol.89, pp.1194-1198, 2004.

I. Dobo, Standardization and comparison of endogenous erythroid colony assays performed with bone marrow or blood progenitors for the diagnosis of polycythemia vera, The Hematology Journal, vol.5, issue.2, pp.161-167, 2004.
DOI : 10.1038/sj.thj.6200344

F. Cervantes, F. Passamonti, and G. Barosi, Life expectancy and prognostic factors in the classic BCR/ABL-negative myeloproliferative disorders, Leukemia, vol.110, issue.5, pp.905-914, 2008.
DOI : 10.1038/leu.2008.72

F. Passamonti, Life expectancy and prognostic factors for survival in patients with polycythemia vera and essential thrombocythemia, The American Journal of Medicine, vol.117, issue.10, pp.755-761, 2004.
DOI : 10.1016/j.amjmed.2004.06.032

I. Dobo, A standardized endogenous megakaryocytic erythroid colony assay for the diagnosis of essential thrombocythemia, Haematologica, vol.89, pp.1207-1212, 2004.

M. Hultcrantz, Patterns of Survival Among Patients With Myeloproliferative Neoplasms Diagnosed in Sweden From 1973 to 2008: A Population-Based Study, Journal of Clinical Oncology, vol.30, issue.24
DOI : 10.1200/JCO.2012.42.1925

F. Cervantes, New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment, Blood, vol.113, issue.13, pp.2895-2901, 2009.
DOI : 10.1182/blood-2008-07-170449

G. Q. Daley, R. A. Van-etten, and D. Baltimore, Induction of chronic myelogenous leukemia in mice by the P210bcr/abl gene of the Philadelphia chromosome, Science, vol.247, issue.4944, pp.824-830, 1990.
DOI : 10.1126/science.2406902

N. Gangat, Cytogenetic studies at diagnosis in polycythemia vera: clinical and JAK2V617F allele burden correlates, European Journal of Haematology, vol.66, issue.3, pp.197-200, 2008.
DOI : 10.1002/ajh.2830110105

N. Gangat, Cytogenetic abnormalities in essential thrombocythemia: prevalence and prognostic significance, European Journal of Haematology, vol.255, issue.1, pp.17-21, 2009.
DOI : 10.1111/j.1600-0609.2009.01246.x

N. Gangat, DIPSS Plus: A Refined Dynamic International Prognostic Scoring System for Primary Myelofibrosis That Incorporates Prognostic Information From Karyotype, Platelet Count, and Transfusion Status, Journal of Clinical Oncology, vol.29, issue.4, pp.392-397, 2011.
DOI : 10.1200/JCO.2010.32.2446

J. Gotlib, World Health Organization-defined eosinophilic disorders: 2014 update on diagnosis, risk stratification, and management, American Journal of Hematology, vol.72, issue.3, pp.325-337, 2014.
DOI : 10.1002/ajh.23664

A. Tefferi, S. Verstovsek, and A. Pardanani, How we diagnose and treat WHO-defined systemic mastocytosis in adults, Haematologica, vol.93, issue.1, pp.6-9, 2008.
DOI : 10.3324/haematol.12324

V. Ugo, Multiple signaling pathways are involved in erythropoietin-independent differentiation of erythroid progenitors in polycythemia vera, Experimental Hematology, vol.32, issue.2, pp.179-187, 2004.
DOI : 10.1016/j.exphem.2003.11.003

C. James, A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera, Nature, vol.100, issue.7037, pp.1144-1148, 2005.
DOI : 10.1182/blood-2002-09-2839

R. Kralovics, in Myeloproliferative Disorders, New England Journal of Medicine, vol.352, issue.17, pp.1779-1790, 2005.
DOI : 10.1056/NEJMoa051113

E. J. Baxter, Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders, The Lancet, vol.365, issue.9464, pp.1054-1061, 2005.
DOI : 10.1016/S0140-6736(05)74230-6

R. L. Levine, Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis, Cancer Cell, vol.7, issue.4, pp.387-397, 2005.
DOI : 10.1016/j.ccr.2005.03.023

P. Saharinen and O. Silvennoinen, The Pseudokinase Domain Is Required for Suppression of Basal Activity of Jak2 and Jak3 Tyrosine Kinases and for Cytokine-inducible Activation of Signal Transduction, Journal of Biological Chemistry, vol.277, issue.49, pp.47954-47963, 2002.
DOI : 10.1074/jbc.M205156200

W. Vainchenker, F. Delhommeau, S. N. Constantinescu, and O. A. Bernard, New mutations and pathogenesis of myeloproliferative neoplasms, Blood, vol.118, issue.7, pp.1723-1735, 2011.
DOI : 10.1182/blood-2011-02-292102

J. ?. Kiladjian, The impact of JAK2 and MPL mutations on diagnosis and prognosis of splanchnic vein thrombosis: a report on 241 cases, Blood, vol.111, issue.10, pp.4922-4929, 2008.
DOI : 10.1182/blood-2007-11-125328

J. H. Smalberg, Myeloproliferative neoplasms in Budd-Chiari syndrome and portal vein thrombosis: a meta-analysis, Blood, vol.120, issue.25, pp.4921-4928, 2012.
DOI : 10.1182/blood-2011-09-376517

A. Renneville, High occurrence of JAK2 V617 mutation in refractory anemia with ringed sideroblasts associated with marked thrombocytosis, Leukemia, vol.131, issue.11, pp.2067-2070, 2006.
DOI : 10.1038/sj.leu.2404069

D. P. Steensma, MPL W515 and JAK2 V617 mutation analysis in patients with refractory anemia with ringed sideroblasts and an elevated platelet count, Haematologica, vol.91, p.57, 2006.

S. A. Wang, Refractory anemia with ringed sideroblasts associated with marked thrombocytosis harbors JAK2 mutation and shows overlapping myeloproliferative and myelodysplastic features, Leukemia, vol.87, issue.9, pp.1641-1644, 2006.
DOI : 10.1038/sj.leu.2404316

J. Jelinek, JAK2 mutation 1849G>T is rare in acute leukemias but can be found in CMML, Philadelphia chromosome-negative CML, and megakaryocytic leukemia, Blood, vol.106, issue.10, pp.3370-3373, 2005.
DOI : 10.1182/blood-2005-05-1800

A. V. Jones, Widespread occurrence of the JAK2 V617F mutation in chronic myeloproliferative disorders, Blood, vol.106, issue.6, pp.2162-2168, 2005.
DOI : 10.1182/blood-2005-03-1320

D. P. Steensma, The JAK2 V617F activating tyrosine kinase mutation is an infrequent event in both "atypical" myeloproliferative disorders and myelodysplastic syndromes, Blood, vol.106, issue.4, pp.1207-1209, 2005.
DOI : 10.1182/blood-2005-03-1183

E. Rumi, JAK2 or CALR mutation status defines subtypes of essential thrombocythemia with substantially different clinical course and outcomes, Blood, vol.123, issue.10, pp.10-1182, 2013.
DOI : 10.1182/blood-2013-11-539098

R. Tiedt, Ratio of mutant JAK2-V617F to wild-type Jak2 determines the MPD phenotypes in transgenic mice, Blood, vol.111, issue.8, pp.3931-3940, 2008.
DOI : 10.1182/blood-2007-08-107748

H. Akada, Conditional expression of heterozygous or homozygous Jak2V617F from its endogenous promoter induces a polycythemia vera-like disease, Blood, vol.115, issue.17, pp.3589-3597, 2010.
DOI : 10.1182/blood-2009-04-215848

C. James, The JAK2V617F Mutation in Polycythemia Vera and Other Myeloproliferative Disorders: One Mutation for Three Diseases?, Hematology, vol.2008, issue.1, 2008.
DOI : 10.1182/asheducation-2008.1.69

L. M. Scott, Exon 12 Mutations in Polycythemia Vera and Idiopathic Erythrocytosis, New England Journal of Medicine, vol.356, issue.5, pp.459-468, 2007.
DOI : 10.1056/NEJMoa065202

D. Pietra, Somatic mutations of JAK2 exon 12 in patients with JAK2 (V617F)-negative myeloproliferative disorders, Blood, vol.111, issue.3, pp.1686-1689, 2008.
DOI : 10.1182/blood-2007-07-101576

E. Kouroupi, Mutations in exon 12 of JAK2 are mainly found in JAK2 V617F-negative polycythaemia vera patients, British Journal of Haematology, vol.35, issue.4, pp.676-679, 2008.
DOI : 10.1111/j.1365-2141.2008.07223.x

M. J. Percy, The frequency of JAK2 exon 12 mutations in idiopathic erythrocytosis patients with low serum erythropoietin levels, Haematologica, vol.92, issue.12, pp.1607-1614, 2007.
DOI : 10.3324/haematol.11643

D. M. Williams, A. H. Kim, O. Rogers, J. L. Spivak, and A. R. Moliterno, Phenotypic variations and new mutations in JAK2 V617F???negative polycythemia vera, erythrocytosis, and idiopathic myelofibrosis, Experimental Hematology, vol.35, issue.11, pp.1641-1646, 2007.
DOI : 10.1016/j.exphem.2007.08.010

F. Passamonti, Molecular and clinical features of the myeloproliferative neoplasm associated with JAK2 exon 12 mutations, Blood, vol.117, issue.10, pp.2813-2816, 2011.
DOI : 10.1182/blood-2010-11-316810

F. Passamonti, A prospective study of 338 patients with polycythemia vera: the impact of JAK2 (V617F) allele burden and leukocytosis on fibrotic or leukemic disease transformation and vascular complications, Leukemia, vol.22, issue.9, pp.1574-1579, 2010.
DOI : 10.1038/leu.2010.148

A. Tefferi, Proposals and rationale for revision of the World Health Organization diagnostic criteria for polycythemia vera, essential thrombocythemia, and primary myelofibrosis: recommendations from an ad hoc international expert panel, Blood, vol.110, issue.4, pp.1092-1097, 2007.
DOI : 10.1182/blood-2007-04-083501

Y. Pikman, MPLW515L Is a Novel Somatic Activating Mutation in Myelofibrosis with Myeloid Metaplasia, PLoS Medicine, vol.102, issue.7, p.270, 2006.
DOI : 10.1371/journal.pmed.0030270.st001

A. D. Pardanani, MPL515 mutations in myeloproliferative and other myeloid disorders: a study of 1182 patients, Blood, vol.108, issue.10, pp.3472-3476, 2006.
DOI : 10.1182/blood-2006-04-018879

A. M. Vannucchi, Characteristics and clinical correlates of MPL 515W>L/K mutation in essential thrombocythemia, Blood, vol.112, issue.3, pp.844-847, 2008.
DOI : 10.1182/blood-2008-01-135897

P. Guglielmelli, mutation, British Journal of Haematology, vol.365, issue.3, pp.244-247, 2007.
DOI : 10.1182/blood-2002-04-1199

URL : https://hal.archives-ouvertes.fr/hal-00535077

S. Schnittger, Characterization of 35 new cases with four different MPLW515 mutations and essential thrombocytosis or primary myelofibrosis, Haematologica, vol.94, issue.1, pp.141-144, 2009.
DOI : 10.3324/haematol.13224

P. A. Beer, MPL mutations in myeloproliferative disorders: analysis of the PT-1 cohort, Blood, vol.112, issue.1, pp.141-149, 2008.
DOI : 10.1182/blood-2008-01-131664

J. Ding, Familial essential thrombocythemia associated with a dominant-positive activating mutation of the c-MPL gene, which encodes for the receptor for thrombopoietin, Blood, vol.103, issue.11, pp.4198-4200, 2004.
DOI : 10.1182/blood-2003-10-3471

K. Liu, Evidence for a founder effect of the MPL-S505N mutation in eight Italian pedigrees with hereditary thrombocythemia, Haematologica, vol.94, issue.10, pp.1368-1374, 2009.
DOI : 10.3324/haematol.2009.005918

R. Chaligné, Evidence for MPL W515L/K mutations in hematopoietic stem cells in primitive myelofibrosis, Blood, vol.110, issue.10, pp.3735-3743, 2007.
DOI : 10.1182/blood-2007-05-089003

A. Pardanani, W515 Mutation Analysis to Single Hematopoietic Colonies and B and T Lymphocytes, STEM CELLS, vol.131, issue.9, pp.2358-2362, 2007.
DOI : 10.1634/stemcells.2007-0175

G. Rotunno, Impact of calreticulin mutations on clinical and hematological phenotype and outcome in essential thrombocythemia, Blood, vol.123, issue.10, 2013.
DOI : 10.1182/blood-2013-11-538983

F. Delhommeau, in Myeloid Cancers, New England Journal of Medicine, vol.360, issue.22, pp.2289-2301, 2009.
DOI : 10.1056/NEJMoa0810069

A. Tefferi, TET2 mutations and their clinical correlates in polycythemia vera, essential thrombocythemia and myelofibrosis, Leukemia, vol.22, issue.5, pp.905-911, 2009.
DOI : 10.1038/leu.2009.47

A. Green and P. Beer, in the Leukemic Transformation of Myeloproliferative Neoplasms, New England Journal of Medicine, vol.362, issue.4, pp.369-370, 2010.
DOI : 10.1056/NEJMc0910063

A. Pardanani, IDH1 and IDH2 mutation analysis in chronic- and blast-phase myeloproliferative neoplasms, Leukemia, vol.28, issue.6, pp.1146-1151, 2010.
DOI : 10.1084/jem.20092506

A. Tefferi, IDH1 and IDH2 mutation studies in 1473 patients with chronic-, fibrotic- or blast-phase essential thrombocythemia, polycythemia vera or myelofibrosis, Leukemia, vol.114, issue.7, pp.1302-1309, 2010.
DOI : 10.1182/blood-2008-12-194548

T. Ernst, Inactivating mutations of the histone methyltransferase gene EZH2 in myeloid disorders, Nature Genetics, vol.8, issue.8, pp.722-726, 2010.
DOI : 10.1016/j.molcel.2008.10.016

P. Guglielmelli, EZH2 mutational status predicts poor survival in myelofibrosis, Blood, vol.118, issue.19, pp.5227-5234, 2011.
DOI : 10.1182/blood-2011-06-363424

O. Abdel?wahab, Concomitant analysis of EZH2 and ASXL1 mutations in myelofibrosis, chronic myelomonocytic leukemia and blast-phase myeloproliferative neoplasms, Leukemia, vol.25, issue.7, pp.1200-1202, 2011.
DOI : 10.1182/blood-2010-06-293415

V. Gelsi?boyer, Mutations in ASXL1 are associated with poor prognosis across the spectrum of malignant myeloid diseases, Journal of Hematology & Oncology, vol.5, issue.1, p.12, 2012.
DOI : 10.1182/blood-2009-07-235358

URL : https://hal.archives-ouvertes.fr/inserm-00698796

B. L. Stein, Disruption of the ASXL1 gene is frequent in primary, post-essential thrombocytosis and post-polycythemia vera myelofibrosis, but not essential thrombocytosis or polycythemia vera: analysis of molecular genetics and clinical phenotypes, Haematologica, vol.96, issue.10, pp.1462-1469, 2011.
DOI : 10.3324/haematol.2011.045591

F. Stegelmann, DNMT3A mutations in myeloproliferative neoplasms, Leukemia, vol.25, issue.7, pp.1217-1219, 2011.
DOI : 10.1056/NEJMoa1005143

O. Abdel?wahab, DNMT3A mutational analysis in primary myelofibrosis, chronic myelomonocytic leukemia and advanced phases of myeloproliferative neoplasms, Leukemia, vol.25, issue.7, pp.1219-1220, 2011.
DOI : 10.1182/blood-2009-09-245837

M. Brecqueville, Rare mutations in DNMT3A in myeloproliferative neoplasms and myelodysplastic syndromes, Blood Cancer Journal, vol.24, issue.5, p.18, 2011.
DOI : 10.1038/bcj.2011.15

T. L. Lasho, SRSF2 mutations in primary myelofibrosis: significant clustering with IDH mutations and independent association with inferior overall and leukemia-free survival, Blood, vol.120, issue.20, pp.4168-4171, 2012.
DOI : 10.1182/blood-2012-05-429696

T. L. Lasho, SF3B1 mutations in primary myelofibrosis: clinical, histopathology and genetic correlates among 155 patients, Leukemia, vol.3, issue.5, pp.1135-1137, 2012.
DOI : 10.1038/leu.2011.320

A. Tefferi, U2AF1 mutations in primary myelofibrosis are strongly associated with anemia and thrombocytopenia despite clustering with JAK2V617F and normal karyotype, Leukemia, vol.119, issue.2, pp.431-433, 2014.
DOI : 10.1038/leu.2013.286

F. H. Grand, Frequent CBL mutations associated with 11q acquired uniparental disomy in myeloproliferative neoplasms, Blood, vol.113, issue.24, pp.6182-6192, 2009.
DOI : 10.1182/blood-2008-12-194548

S. Schnittger, Use of CBL exon 8 and 9 mutations in diagnosis of myeloproliferative neoplasms and myelodysplastic/myeloproliferative disorders: an analysis of 636 cases, Haematologica, vol.97, issue.12, pp.1890-1894, 2012.
DOI : 10.3324/haematol.2012.065375

P. Aranaz, CBL mutations in myeloproliferative neoplasms are also found in the gene's proline-rich domain and in patients with the V617FJAK2, Haematologica, vol.97, issue.8, pp.1234-1241, 2012.
DOI : 10.3324/haematol.2011.052605

S. Gery, Lnk inhibits myeloproliferative disorder-associated JAK2 mutant, JAK2V617F, Journal of Leukocyte Biology, vol.85, issue.6, pp.957-965, 2009.
DOI : 10.1189/jlb.0908575

T. L. Lasho, A. Pardanani, and A. Tefferi, Mutation???Negative Erythrocytosis, New England Journal of Medicine, vol.363, issue.12, pp.1189-1190, 2010.
DOI : 10.1056/NEJMc1006966

A. Pardanani, LNK mutation studies in blast-phase myeloproliferative neoplasms, and in chronic-phase disease with TET2, IDH, JAK2 or MPL mutations, Leukemia, vol.118, issue.10, pp.1713-1718, 2010.
DOI : 10.1158/0008-5472.CAN-09-3783

R. Jäger, Deletions of the transcription factor Ikaros in myeloproliferative neoplasms, Leukemia, vol.85, issue.7, pp.1290-1298, 2010.
DOI : 10.1073/pnas.0811761106

P. A. Beer, Two routes to leukemic transformation after a JAK2 mutation-positive myeloproliferative neoplasm, Blood, vol.115, issue.14, pp.2891-2900, 2010.
DOI : 10.1182/blood-2009-08-236596

A. Harutyunyan, T. Klampfl, M. Cazzola, and R. Kralovics, p53 Lesions in Leukemic Transformation, p53 Lesions in Leukemic Transformation, pp.488-490, 2011.
DOI : 10.1056/NEJMc1012718

K. Bedard, E. Szabo, M. Michalak, and M. Opas, Cellular Functions of Endoplasmic Reticulum Chaperones Calreticulin, Calnexin, and ERp57, International Review of Cytology, vol.245, pp.91-121, 2005.
DOI : 10.1016/S0074-7696(05)45004-4

M. Michalak, J. Groenendyk, E. Szabo, L. I. Gold, and M. Opas, Calreticulin, a multi-process calcium-buffering chaperone of the endoplasmic reticulum, Biochemical Journal, vol.417, issue.3, p.651, 2009.
DOI : 10.1042/BJ20081847

L. Ellgaard, E. Frickel, and . ?m, Calnexin, Calreticulin, and ERp57: Teammates in Glycoprotein Folding, Cell Biochemistry and Biophysics, vol.39, issue.3, pp.223-247, 2003.
DOI : 10.1385/CBB:39:3:223

L. Ellgaard and A. Helenius, Quality control in the endoplasmic reticulum, Nature Reviews Molecular Cell Biology, vol.418, issue.3
DOI : 10.1038/nrm1052

D. B. Williams, Beyond lectins: the calnexin/calreticulin chaperone system of the endoplasmic reticulum, Journal of Cell Science, vol.119, issue.4, pp.615-623, 2006.
DOI : 10.1242/jcs.02856

L. I. Gold, Calreticulin: non-endoplasmic reticulum functions in physiology and disease, The FASEB Journal, vol.24, issue.3, pp.665-683, 2010.
DOI : 10.1096/fj.09-145482

M. Zamanian, A. Veerakumarasivam, S. Abdullah, and R. Rosli, Calreticulin and Cancer, Pathology & Oncology Research, vol.174, issue.2, pp.149-154, 2013.
DOI : 10.1007/s12253-012-9600-2

M. P. Chao, Calreticulin Is the Dominant Pro-Phagocytic Signal on Multiple Human Cancers and Is Counterbalanced by CD47, Science Translational Medicine, vol.2, issue.63, pp.63-94, 2010.
DOI : 10.1126/scitranslmed.3001375

W. W. Pang, Hematopoietic stem cell and progenitor cell mechanisms in myelodysplastic syndromes, Proceedings of the National Academy of Sciences, vol.110, issue.8, pp.3011-3016, 2013.
DOI : 10.1073/pnas.1222861110

D. Helbling, CBFB-SMMHC is correlated with increased calreticulin expression and suppresses the granulocytic differentiation factor CEBPA in AML with inv(16), Blood, vol.106, issue.4, pp.1369-1375, 2005.
DOI : 10.1182/blood-2004-11-4392

D. Helbling, The leukemic fusion gene AML1-MDS1-EVI1 suppresses CEBPA in acute myeloid leukemia by activation of Calreticulin, Proceedings of the National Academy of Sciences, vol.101, issue.36, pp.13312-13317, 2004.
DOI : 10.1073/pnas.0404731101

T. Klampfl, Somatic Mutations of Calreticulin in Myeloproliferative Neoplasms, New England Journal of Medicine, vol.369, issue.25, pp.2379-2390, 2013.
DOI : 10.1056/NEJMoa1311347

A. Tefferi, CALR vs JAK2 vs MPL-mutated or triple-negative myelofibrosis: clinical, cytogenetic and molecular comparisons, Leukemia, vol.26, issue.7, 2014.
DOI : 10.1038/leu.2014.3

A. Tefferi, Calreticulin mutations and long-term survival in essential thrombocythemia, Leukemia, vol.120, issue.12, 2014.
DOI : 10.1038/leu.2014.148

A. Tefferi, Type 1 versus Type 2 calreticulin mutations in essential thrombocythemia: A collaborative study of 1027 patients, American Journal of Hematology, vol.33, issue.8, pp.121-124, 2014.
DOI : 10.1002/ajh.23743

J. Broséus, Low rate of calreticulin mutations in refractory anaemia with ring sideroblasts and marked thrombocytosis, Leukemia, vol.91, issue.6, 2014.
DOI : 10.3324/haematol.13224

M. M. Patnaik, CALR mutations are infrequent in WHO-defined refractory anemia with ring sideroblasts, Leukemia, vol.87, issue.6, pp.1370-1371, 2014.
DOI : 10.1038/leu.2011.320

H. ?. Hou, Y. ?. Kuo, W. ?. Chou, P. ?. Chen, H. Tien et al., Calreticulin mutation was rarely detected in patients with myelodysplastic syndrome, Leukemia, vol.12, issue.7, 2014.
DOI : 10.1038/leu.2014.71

S. E. Langabeer, K. Haslam, and C. Mcmahon, mutations are rare in childhood essential thrombocythemia, Pediatric Blood & Cancer, vol.369, issue.8, p.1523, 2014.
DOI : 10.1002/pbc.24984

F. Giona, CALR mutations in patients with essential thrombocythemia diagnosed in childhood and adolescence, Blood, vol.123, issue.23, pp.3677-3679, 2014.
DOI : 10.1182/blood-2014-04-572040

W. An, CALR mutation screening in pediatric primary myelofibrosis, Pediatric Blood & Cancer, vol.68, issue.12, 2014.
DOI : 10.1002/pbc.25211

P. Lundberg, Somatic mutations in calreticulin can be found in pedigrees with familial predisposition to myeloproliferative neoplasms, Blood, vol.123, issue.17, pp.2744-2745, 2014.
DOI : 10.1182/blood-2014-01-550863

M. Maffioli, Looking for CALR mutations in familial myeloproliferative neoplasms, Leukemia, vol.2, issue.6, pp.1357-1360, 2014.
DOI : 10.1182/blood-2007-04-083501

E. Rumi, CALR exon 9 mutations are somatically acquired events in familial cases of essential thrombocythemia or primary myelofibrosis, Blood, vol.123, issue.15, pp.2416-2419, 2014.
DOI : 10.1182/blood-2014-01-550434

F. Turon, Role of calreticulin mutations in the etiological diagnosis of splanchnic vein thrombosis, J. Hepatol, 2014.

K. Haslam and S. E. Langabeer, Incidence of CALR mutations in patients with splanchnic vein thrombosis, Br. J. Haematol, 2014.

L. Eder?azanza, Bioinformatic analyses of CALR mutations in myeloproliferative neoplasms support a role in signaling, Leukemia, vol.103, issue.10, 2014.
DOI : 10.1038/leu.2014.190

J. Chi, Calreticulin gene exon 9 frameshift mutations in patients with thrombocytosis, Leukemia, vol.88, issue.5, pp.1152-1154, 2014.
DOI : 10.1111/j.1365-2141.2010.08122.x

P. Lundberg, Clonal evolution and clinical correlates of somatic mutations in myeloproliferative neoplasms, Blood, vol.123, issue.14, pp.2220-2228, 2014.
DOI : 10.1182/blood-2013-11-537167

A. Tefferi, Type 1 vs type 2 calreticulin mutations in primary myelofibrosis: differences in phenotype and prognostic impact, Leukemia, vol.114, issue.7, pp.1568-1570, 2014.
DOI : 10.1038/leu.2014.83

A. Tefferi, Long-term survival and blast transformation in molecularly annotated essential thrombocythemia, polycythemia vera, and myelofibrosis, Blood, vol.124, issue.16, pp.10-1182, 2014.
DOI : 10.1182/blood-2014-05-579136

P. Guglielmelli, The number of prognostically detrimental mutations and prognosis in primary myelofibrosis: an international study of 797 patients, Leukemia, vol.122, issue.9, 2014.
DOI : 10.1038/leu.2014.76

V. Panagiota, Prognostic effect of calreticulin mutations in patients with myelofibrosis after allogeneic hematopoietic stem cell transplantation, Leukemia, vol.115, issue.7, 2014.
DOI : 10.1038/leu.2014.66

A. P. Trifa, CALR versus JAK2 mutated essential thrombocythaemia ? a report on 141 patients, Br. J. Haematol, 2014.

C. Qiao, Clinical importance of different calreticulin gene mutation types in wildtype JAK2 essential thrombocythemia and myelofibrosis patients, Haematologica, 2014.

H. Andrikovics, Distinct clinical characteristics of myeloproliferative neoplasms with calreticulin mutations, Haematologica, vol.99, issue.7, pp.1184-1190, 2014.
DOI : 10.3324/haematol.2014.107482

C. ?. Chen, Frequencies, clinical characteristics, and outcome of somatic CALR mutations in JAK2-unmutated essential thrombocythemia, Annals of Hematology, vol.117, issue.12, 2014.
DOI : 10.1007/s00277-014-2151-8

H. Shen, CALR and ASXL1 mutation analysis in 190 patients with essential thrombocythemia, Leuk. Lymphoma, vol.1, issue.9, 2014.

B. Li, Calreticulin mutations in Chinese with primary myelofibrosis, Haematologica, vol.99, issue.11, 2014.
DOI : 10.3324/haematol.2014.109249

X. Cabagnols, Differential association of calreticulin type 1 and type 2 mutations with myelofibrosis and essential thrombocytemia: relevance for disease evolution, Leukemia, vol.29, issue.1, 2014.
DOI : 10.1182/blood-2014-02-554634

URL : https://hal.archives-ouvertes.fr/hal-01258918

A. Tefferi, CALR and ASXL1 mutations-based molecular prognostication in primary myelofibrosis: an international study of 570 patients, Leukemia, vol.54, issue.7, pp.1494-1500, 2014.
DOI : 10.1038/leu.2014.57

B. Cassinat, E. Verger, J. Kiladjian, and . ?j, -Mutated Essential Thrombocythemia, New England Journal of Medicine, vol.371, issue.2, pp.188-189, 2014.
DOI : 10.1056/NEJMc1401255

URL : https://hal.archives-ouvertes.fr/hal-01276534

F. Passamonti, D. Caramazza, and M. Maffioli, JAK inhibitor in CALR?mutant myelofibrosis, N. Engl. J. Med, vol.370, pp.1168-1169, 2014.

A. M. Vannucchi, Calreticulin mutation-specific immunostaining in myeloproliferative neoplasms: pathogenetic insight and diagnostic value, Leukemia, vol.277, issue.9, 2014.
DOI : 10.1038/leu.2014.100

J. ?. Kiladjian, Essential thrombocythemias without V617F JAK2 mutation are clonal hematopoietic stem cell disorders, Leukemia, vol.366, issue.6, pp.1181-1183, 2006.
DOI : 10.1038/sj.leu.2404214

E. Lippert, The JAK2-V617F mutation is frequently present at diagnosis in patients with essential thrombocythemia and polycythemia vera, Blood, vol.108, issue.6, pp.1865-1867, 2006.
DOI : 10.1182/blood-2006-01-013540

F. Fantasia, A highly specific q-RT-PCR assay to address the relevance of the JAK2WT and JAK2V617F expression levels and control genes in Ph-negative myeloproliferative neoplasms, Annals of Hematology, vol.110, issue.4, pp.609-616, 2014.
DOI : 10.1007/s00277-013-1920-0

A. R. Moliterno, D. M. Williams, O. Rogers, and J. L. Spivak, Molecular mimicry in the chronic myeloproliferative disorders: reciprocity between quantitative JAK2 V617F and Mpl expression, Blood, vol.108, issue.12, pp.3913-3915, 2006.
DOI : 10.1182/blood-2006-03-008805

B. Bellosillo, A higher JAK2 V617F-mutated clone is observed in platelets than in granulocytes from essential thrombocythemia patients, but not in patients with polycythemia vera and primary myelofibrosis, Leukemia, vol.365, issue.6, pp.1331-1332, 2007.
DOI : 10.1038/sj.leu.2404214

R. Zhao, Identification of an Acquired JAK2 Mutation in Polycythemia Vera, Journal of Biological Chemistry, vol.280, issue.24
DOI : 10.1074/jbc.C500138200

A. M. Vannucchi, A. Pancrazzi, C. Bogani, E. Antonioli, and P. Guglielmelli, A quantitative assay for JAK2V617F mutation in myeloproliferative disorders by ARMS-PCR and capillary electrophoresis, Leukemia, vol.127, issue.6, pp.1055-1060, 2006.
DOI : 10.1038/sj.leu.2404209

K. Toyama, JAK2-V617F mutation analysis of granulocytes and platelets from patients with chronic myeloproliferative disorders: advantage of studying platelets, British Journal of Haematology, vol.41, issue.3, pp.64-69, 2007.
DOI : 10.1111/j.1365-2141.2005.05764.x

C. N. Harrison, Guideline for investigation and management of adults and children presenting with a thrombocytosis, British Journal of Haematology, vol.100, issue.Suppl 1, pp.352-375, 2010.
DOI : 10.1111/j.1365-2141.2010.08122.x

T. S. Larsen, N. Pallisgaard, M. B. Møller, and H. C. Hasselbalch, The JAK2 V617F allele burden in essential thrombocythemia, polycythemia vera and primary myelofibrosis ??? impact on disease phenotype, European Journal of Haematology, vol.365, issue.6, pp.508-515, 2007.
DOI : 10.1038/sj.leu.2404209

A. L. Godfrey, JAK2V617F homozygosity arises commonly and recurrently in PV and ET, but PV is characterized by expansion of a dominant homozygous subclone, Blood, vol.120, issue.13, pp.2704-2707, 2012.
DOI : 10.1182/blood-2012-05-431791

C. Allen, J. R. Lambert, D. C. Linch, and R. E. Gale, X chromosome inactivation analysis reveals a difference in the biology of ET patients with JAK2 and CALR mutations, Blood, vol.124, issue.13, pp.10-1182, 2014.
DOI : 10.1182/blood-2014-06-580183

R. Kralovics, Acquisition of the V617F mutation of JAK2 is a late genetic event in a subset of patients with myeloproliferative disorders, Blood, vol.108, issue.4, pp.1377-1380, 2006.
DOI : 10.1182/blood-2005-11-009605

A. M. Vannucchi, Clinical profile of homozygous JAK2 617V>F mutation in patients with polycythemia vera or essential thrombocythemia, Blood, vol.110, issue.3, pp.840-846, 2007.
DOI : 10.1182/blood-2006-12-064287

A. Tefferi, Low JAK2V617F allele burden in primary myelofibrosis, compared to either a higher allele burden or unmutated status, is associated with inferior overall and leukemia-free survival, Leukemia, vol.22, issue.4, pp.756-761, 2008.
DOI : 10.1038/sj.leu.2404750

P. Guglielmelli, Identification of patients with poorer survival in primary myelofibrosis based on the burden of JAK2V617F mutated allele, Blood, vol.114, issue.8, pp.1477-1483, 2009.
DOI : 10.1182/blood-2009-04-216044

A. M. Vannucchi, Prospective identification of high-risk polycythemia vera patients based on JAK2V617F allele burden, Leukemia, vol.290, issue.9, pp.1952-1959, 2007.
DOI : 10.1182/blood-2006-03-009860

A. Carobbio, JAK2V617F allele burden and thrombosis: A direct comparison in essential thrombocythemia and polycythemia vera, Experimental Hematology, vol.37, issue.9, pp.1016-1021, 2009.
DOI : 10.1016/j.exphem.2009.06.006

A. M. Vannucchi, L. Pieri, and P. Guglielmelli, allele burden in the myeloproliferative neoplasms: effects on phenotype, prognosis and change with treatment, Therapeutic Advances in Hematology, vol.1, issue.1, pp.21-32, 2011.
DOI : 10.1182/blood-2005-09-3900

P. J. Campbell, V617F mutation in JAK2 is associated with poorer survival in idiopathic myelofibrosis, Blood, vol.107, issue.5, pp.2098-2100, 2006.
DOI : 10.1182/blood-2005-08-3395

URL : https://hal.archives-ouvertes.fr/hal-00453286

A. Tefferi, The JAK2V617F tyrosine kinase mutation in myelofibrosis with myeloid metaplasia: lineage specificity and clinical correlates, British Journal of Haematology, vol.59, issue.3, pp.320-328, 2005.
DOI : 10.1074/jbc.C500138200

G. Barosi, JAK2 V617F mutational status predicts progression to large splenomegaly and leukemic transformation in primary myelofibrosis, Blood, vol.110, issue.12, pp.4030-4036, 2007.
DOI : 10.1182/blood-2007-07-099184

P. Guglielmelli, Identification of patients with poorer survival in primary myelofibrosis based on the burden of JAK2V617F mutated allele, Blood, vol.114, issue.8, pp.1477-1483, 2009.
DOI : 10.1182/blood-2009-04-216044

K. Haslam, S. E. Langabeer, K. Molloy, M. F. Mcmullin, and E. Conneally, Assessment of CALR mutations in myelofibrosis patients, post?allogeneic stem cell transplantation

J. ?. Kiladjian, Pegylated interferon-alfa-2a induces complete hematologic and molecular responses with low toxicity in polycythemia vera, Blood, vol.112, issue.8, pp.3065-3072, 2008.
DOI : 10.1182/blood-2008-03-143537

F. Girodon, Frequent reduction or absence of detection of the JAK2-mutated clone in JAK2V617F-positive patients within the first years of hydroxyurea therapy, Haematologica, vol.93, issue.11, pp.1723-1727, 2008.
DOI : 10.3324/haematol.13081

H. Alchalby, Impact of JAK2V617F mutation status, allele burden, and clearance after allogeneic stem cell transplantation for myelofibrosis, Blood, vol.116, issue.18, pp.3572-3581, 2010.
DOI : 10.1182/blood-2009-12-260588

E. Lippert, Clinical and biological characterization of patients with low (0.1-2%) JAK2V617F allele burden at diagnosis, Haematologica, vol.99, issue.7, pp.98-101, 2014.
DOI : 10.3324/haematol.2014.107656

URL : https://hal.archives-ouvertes.fr/inserm-01402419

S. Hermouet, Comparison of whole blood vs purified blood granulocytes for the detection and quantitation of JAK2(V617F), Leukemia, vol.21, pp.1128-1130, 2007.

F. Delhommeau, Evidence that the JAK2 G1849T (V617F) mutation occurs in a lymphomyeloid progenitor in polycythemia vera and idiopathic myelofibrosis, Blood, vol.109, issue.1, pp.71-77, 2007.
DOI : 10.1182/blood-2006-03-007146

T. Ishii, E. Bruno, R. Hoffman, and M. Xu, Involvement of various hematopoietic-cell lineages by the JAK2V617F mutation in polycythemia vera, Blood, vol.108, issue.9, pp.3128-3134, 2006.
DOI : 10.1182/blood-2006-04-017392

S. Li, Clonal heterogeneity in polycythemia vera patients with JAK2 exon12 and JAK2-V617F mutations, Blood, vol.111, issue.7, pp.3863-3866, 2008.
DOI : 10.1182/blood-2007-09-111971

H. ?. Kim, Allelic Expression Imbalance of JAK2 V617F Mutation in BCR-ABL Negative Myeloproliferative Neoplasms, PLoS ONE, vol.106, issue.1, p.52518, 2013.
DOI : 10.1371/journal.pone.0052518.s008